BioInnovatise Launches New Adenovirus Packaging Service for Accelerating Research and Development
November 18, 2024
Rockville, MD — BioInnovatise is proud to announce the introduction of its new Adenovirus Packaging Service, designed to enhance the capabilities of early discovery phase research and development. As part of our commitment to advancing scientific discovery, BioInnovatise offers fast, reliable, and high quality contract development and manufacturing organization (CDMO) services for viral vector based research, including adenovirus packaging.
With over 30,000 cloning constructs produced, 100+ lentiviral vectors packaged, and more than 1,000 plasmid DNA preparations, BioInnovatise is prepared to meet your viral vector, including adenovirus packaging, lentivirus packaging, and retrovirus packaging, needs efficiently. Our quick turnaround times ensure that projects proceed without unnecessary delays.
BioInnovatise’s new adenovirus packaging service perfectly complements our existing retrovirus and lentivirus offerings, providing researchers with a comprehensive range of viral vectors for early discovery-phase R&D. Together, these services give researchers flexible, tailored options to meet the diverse needs of gene therapy, immunology, and oncology research, accelerating progress toward groundbreaking discoveries.